HyBryte™ Skin Directed Therapy for Cutaneous
HyBryte™ is a skin directed therapy with visible light activation for the treatment of early stage CTCL that appears to be safe and well tolerated in clinical trials.
HyBryte™ may enable patients to undergo more treatments to manage their disease while accumulating significantly fewer risks/toxicities.
HyBryte™ is not yet approved for sale in any jurisdiction.
Dr. Ellen Kim Featured on OncologyTube.